7.12 USD
-0.1 (-1.39%)
We assign a fundamental rating of 3 out of 10 to IMA. IMA was compared to 190 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for IMA as it has an excellent financial health rating, but there are worries on the profitability. IMA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- IMA had negative earnings in the past year.
- In the past year IMA has reported a negative cash flow from operations.
- In the past 5 years IMA always reported negative net income.
- In the past 5 years IMA always reported negative operating cash flow.
1.2 Ratios
- IMA's Return On Assets of -30.60% is in line compared to the rest of the industry. IMA outperforms 51.58% of its industry peers.
- IMA's Return On Equity of -35.21% is in line compared to the rest of the industry. IMA outperforms 58.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.6% | ||
| ROE | -35.21% | ||
| ROIC | N/A |
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- IMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- IMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- IMA has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for IMA has been reduced compared to 5 years ago.
- IMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of 0.23, we must say that IMA is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of 0.23, IMA perfoms like the industry average, outperforming 45.79% of the companies in the same industry.
- IMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.23 |
ROIC/WACCN/A
WACC9.37%
2.3 Liquidity
- A Current Ratio of 13.24 indicates that IMA has no problem at all paying its short term obligations.
- IMA has a Current ratio of 13.24. This is amongst the best in the industry. IMA outperforms 82.11% of its industry peers.
- IMA has a Quick Ratio of 13.24. This indicates that IMA is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 13.24, IMA belongs to the top of the industry, outperforming 82.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.24 | ||
| Quick Ratio | 13.24 |
3. Growth
3.1 Past
- IMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.87%, which is quite impressive.
- The Revenue for IMA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)47.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.48%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, IMA will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.28% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y53.37%
EPS Next 2Y31.66%
EPS Next 3Y20.77%
EPS Next 5Y11.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- IMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year IMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as IMA's earnings are expected to grow with 20.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.66%
EPS Next 3Y20.77%
5. Dividend
5.1 Amount
- No dividends for IMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IMAGENEBIO INC / IMA FAQ
Can you provide the ChartMill fundamental rating for IMAGENEBIO INC?
ChartMill assigns a fundamental rating of 3 / 10 to IMA.
Can you provide the valuation status for IMAGENEBIO INC?
ChartMill assigns a valuation rating of 1 / 10 to IMAGENEBIO INC (IMA). This can be considered as Overvalued.
How profitable is IMAGENEBIO INC (IMA) stock?
IMAGENEBIO INC (IMA) has a profitability rating of 1 / 10.
How financially healthy is IMAGENEBIO INC?
The financial health rating of IMAGENEBIO INC (IMA) is 8 / 10.